← Back to news

Markets

1 Social Security Trick That Could Get You Larger Benefits

Y

Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development

Y

Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data

Y

Kroger Stock Outlook: Is Wall Street Bullish or Bearish?

Y

Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets

Y

Here is Why Hedge Funds Favor Advance Auto Parts (AAP)

Y

Autoliv (ALV) Drives Some Near Term Optimism Despite Affordability Concerns

Y

Favorable Sector Outlook Bodes Well for Visteon (VC)

Y

Latest Zero-Emission Offerings Spark Bullish Views on Garrett Motion (GTX)

Y

H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program

Y

Goodyear (GT) Set to Benefit From Favorable Replacement Tire Market Potential

Y

Aptiv (APTV) Looking at More Realistic Value and Growth Propositions

Y

2026 Labeled as a Transition Year for Mobileye (MBLY)

Y

AutoZone (AZO) Showing Ambition Towards Accelerating Store Growth

Y

Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)

Y

Hyperliquid's HYPE higher by 10% on plans to add prediction markets and options

Y

H.C. Wainwright Flag KRRO-121 as Independent Value Driver for Korro Bio, Inc. (KRRO)

Y

Alphabet Inc.’s Google Adds More Gemini AI Features to the Chrome Browser

Y

Here Is Why TSMC Could Be Investing More In the US?

Y

Alibaba Group Holding’s Robovan Unit Set to Invest in Zelos Technology, WSJ Reports

Y

Analysts Remain Bullish on Advanced Micro Devices Despite Rumours of MI450-Series Chips Behind Schedule

Y

Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262

Y

Cathie Wood Remains Bullish on Broadcom Amid AI and Datacenter Exposure

Y

Are Coins a Safe-Haven Asset? What Experts Say for 2026

Y

‘We live on Social Security and pensions’: I’m in my 70s and my house needs repairs. Do I take out a $50K loan — or sell stocks?

Y

Palantir Earnings Arrive Just as Stock Could Use Some Good News

Y

Are Wall Street Analysts Bullish on Morgan Stanley Stock?

Y

Brookfield to Buy Peakstone Realty Trust in $1.2 Billion Deal

Y

C3.ai (AI) Stays Central to AI Debate as Capital Intensity Challenges Investor Confidence

Y

Russia’s Largest Crypto Miner BitRiver Faces Bankruptcy as CEO Under House Arrest: Report

Y

RIA Edge 100 Firms Add Clients, Employees at Roughly Same Pace

Y

'It's All On Paper' – Gymshark Founder, Worth $1.4B, Says You Should Never Link Self-Worth With Money, Thinks It's 'Wildly Unproductive' Way To Live

Y

Tom Lee's BitMine Immersion added 41,000 ether as paper losses rise to $6 billion

Y

1 Under-the-Radar AI Stock With Explosive Growth Potential

Y

H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)’s Carvykti Despite Sales Miss

Y

Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results

Y

Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)

Y

Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal

Y

Cattle Supply Crunch Weighs on Profit at Tyson Foods

Y

Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress

Y

Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007

Y

Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion

Y

Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play

Y

Here’s Why uniQure (QURE) Declined in Q4

Y

ExxonMobil Continues to Prove It's in a League of Its Own

Y

Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances

Y

Europe just started building a ‘kill switch’ for U.S. tech — and the market isn’t priced for it, says this strategist

Y

Fed Chair Nominee Kevin Warsh Has Called Bitcoin The 'New Gold', Yet BTC Is Down 3%

Y

Where’s my refund? These 2 changes at the IRS could slow down your check this tax season

Y

Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts

Y